baccaratset| Heplatinum Pharmaceuticals-B and AstraZeneca enter into a licensing and option agreement for a new tumor-targeted therapy

Heplatinum Pharmaceuticals-B (02142) issued an announcementbaccaratset, Nona Biotech (Suzhou) Co., Ltd., a wholly-owned subsidiary of the company, has entered into a licensing and options agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for preclinical monoclonal antibodies to be used to create tumor-targeted therapies.

Under the agreement, Nona Biotech will: receive a prepayment of US$19 million upon completion of the transaction; receive a recent milestone payment of US$10 million; and charge up to 5 million upon completion of specific development, regulatory and commercial milestones.baccaratset$.75 billion in milestone payments; and receiving tiered royalties based on net sales.

In addition, if AstraZeneca exercises such options, Nona Biotech will be eligible to receive payment for the option plan.